Industry breathes sigh of relief as government drops generic substitution plans for England
This article was originally published in SRA
Executive Summary
The UK coalition government has dropped plans to introduce automatic generic substitution in England after a consultation on the proposals revealed stakeholder concern that the plans could risk patient safety and scepticism at how much the scheme could actually save1,2. The R&D-based pharmaceutical industry appears to be relieved.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.